Literature DB >> 28526802

Macrolide resistance in Pseudomonas aeruginosa: implications for practice.

James D Chalmers1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28526802     DOI： 10.1183/13993003.00689-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  5 in total

1.  Azithromycin Exhibits Activity Against Pseudomonas aeruginosa in Chronic Rat Lung Infection Model.

Authors:  Manoj Kumar; Madhvi Rao; Tarun Mathur; Tarani Kanta Barman; Vattan Joshi; Tridib Chaira; Smita Singhal; Manisha Pandya; Souhaila Al Khodor; Dilip J Upadhyay; Nobuhisa Masuda
Journal:  Front Microbiol       Date:  2021-04-23       Impact factor: 5.640

Review 2.  Mechanism of action, resistance, synergism, and clinical implications of azithromycin.

Authors:  Mohsen Heidary; Ahmad Ebrahimi Samangani; Abolfazl Kargari; Aliakbar Kiani Nejad; Ilya Yashmi; Moloudsadat Motahar; Elahe Taki; Saeed Khoshnood
Journal:  J Clin Lab Anal       Date:  2022-04-21       Impact factor: 3.124

3.  Metagenomics Reveals a Core Macrolide Resistome Related to Microbiota in Chronic Respiratory Disease.

Authors:  Micheál Mac Aogáin; Kenny J X Lau; Zhao Cai; Jayanth Kumar Narayana; Rikky W Purbojati; Daniela I Drautz-Moses; Nicolas E Gaultier; Tavleen K Jaggi; Pei Yee Tiew; Thun How Ong; Mariko Siyue Koh; Albert Lim Yick Hou; John A Abisheganaden; Krasimira Tsaneva-Atanasova; Stephan C Schuster; Sanjay H Chotirmall
Journal:  Am J Respir Crit Care Med       Date:  2020-08-01       Impact factor: 21.405

4.  Azithromycin and the microbiota of cystic fibrosis sputum.

Authors:  Nicole Acosta; Christina S Thornton; Michael G Surette; Ranjani Somayaji; Laura Rossi; Harvey R Rabin; Michael D Parkins
Journal:  BMC Microbiol       Date:  2021-03-30       Impact factor: 3.605

5.  Comparative evaluation of the effect of different growth media on in vitro sensitivity to azithromycin in multi-drug resistant Pseudomonas aeruginosa isolated from cystic fibrosis patients.

Authors:  Michael Sörensen; Bakhodur Khakimov; Dennis Nurjadi; Sébastien Boutin; Buqing Yi; Alexander H Dalpke; Tatjana Eigenbrod
Journal:  Antimicrob Resist Infect Control       Date:  2020-12-09       Impact factor: 4.887
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.